MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
358.33
+5.51
+1.56%
Pre Market: 357.15 -1.18 -0.33% 08:19 06/29 EDT
OPEN
354.69
PREV CLOSE
352.82
HIGH
362.27
LOW
354.16
VOLUME
295
TURNOVER
511.89M
52 WEEK HIGH
388.36
52 WEEK LOW
260.01
MARKET CAP
193.39B
P/E (TTM)
24.91
1D
5D
1M
3M
1Y
5Y
1D
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
Benzinga · 18m ago
Quantinuum receives multiple Buy ratings as it nears fault-tolerant system; TAM expands
Seeking Alpha · 47m ago
VIRIDIAN THERAPEUTICS EXEC SAYS THE WHOLESALE ACQUISITION COST FOR FIVE INFUSIONS OF LUMVOA IS ABOUT $450,000 FOR A TYPICAL 75‑KG PATIENT
Reuters · 1h ago
VIRIDIAN THERAPEUTICS EXEC SAYS FIVE INFUSIONS OF ITS THYROID EYE DISEASE DRUG LUMVOA ARE PRICED ROUGHLY IN LINE WITH EIGHT INFUSIONS OF AMGEN’S TEPEZZA - CONF CALL
Reuters · 1h ago
Analysts’ Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)
TipRanks · 2h ago
Weekly Report: what happened at AMGN last week (0622-0626)?
Weekly Report · 3h ago
Sino Biopharmaceutical Stock Rises 5.4% in Hong Kong
Dow Jones · 5h ago
It's Time To Go All-In On SCHD
Seeking Alpha · 1d ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.